The expression level of c-jun also correlated positively with the sensitivity of breast cancer cells to treatment with GLS inhibitor.18 In our previous study, we found that the high glutaminase activity in breast cancer cells was regulated by Rho GTPases through transcription factor NF-κB.12 This was the first report that glutaminase activity, not its expression level, plays a critical role in cancer progression. The gene discussed is GLS; the disease is breast carcinoma.